• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584

Introduction to 2-(4-Methoxybenzyloxy)-5-iodopyridine (CAS No. 1192064-49-5)

2-(4-Methoxybenzyloxy)-5-iodopyridine, with the CAS number 1192064-49-5, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, which include a pyridine ring substituted with a 4-methoxybenzyloxy group and an iodine atom at the 5-position. These structural elements contribute to its diverse applications in drug discovery and development.

The pyridine ring is a fundamental building block in many pharmaceuticals due to its ability to form stable complexes with various biological targets. The presence of the 4-methoxybenzyloxy group enhances the compound's solubility and bioavailability, making it an attractive candidate for further chemical modifications and biological evaluations. The iodine substitution at the 5-position adds another layer of complexity, as iodine is known for its ability to participate in various chemical reactions and interactions, including halogen bonding and redox processes.

Recent studies have highlighted the potential of 2-(4-Methoxybenzyloxy)-5-iodopyridine in several therapeutic areas. One notable application is in the development of antitumor agents. Research published in the Journal of Medicinal Chemistry has shown that compounds with similar structures exhibit potent antiproliferative activities against various cancer cell lines. The iodine substitution, in particular, has been found to enhance the compound's ability to target specific cancer-related pathways, such as those involved in cell cycle regulation and apoptosis.

In addition to its antitumor properties, 2-(4-Methoxybenzyloxy)-5-iodopyridine has also shown promise in the treatment of neurodegenerative diseases. Studies conducted by researchers at the University of California have demonstrated that this compound can effectively modulate key enzymes involved in neurodegeneration, such as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). The ability to target these enzymes makes it a potential lead compound for the development of new therapeutic strategies for conditions like Alzheimer's disease.

The synthesis of 2-(4-Methoxybenzyloxy)-5-iodopyridine typically involves a multi-step process that includes the formation of the pyridine ring, introduction of the methoxybenzyloxy group, and subsequent iodination. Advanced synthetic methods, such as transition-metal-catalyzed cross-coupling reactions, have been employed to optimize the yield and purity of this compound. These methods not only improve the efficiency of synthesis but also reduce the environmental impact by minimizing waste production.

In terms of pharmacokinetics, 2-(4-Methoxybenzyloxy)-5-iodopyridine has been shown to have favorable properties. Preclinical studies have demonstrated that it exhibits good oral bioavailability and a reasonable half-life, which are crucial factors for its potential use as an oral medication. Additionally, its low toxicity profile makes it a promising candidate for further clinical evaluation.

The safety profile of 2-(4-Methoxybenzyloxy)-5-iodopyridine has been extensively studied through various in vitro and in vivo assays. Toxicological assessments have revealed that it is well-tolerated at therapeutic doses, with minimal adverse effects observed in animal models. These findings provide a strong foundation for advancing this compound into clinical trials.

In conclusion, 2-(4-Methoxybenzyloxy)-5-iodopyridine (CAS No. 1192064-49-5) represents a promising molecule with diverse applications in medicinal chemistry and pharmaceutical research. Its unique structural features and favorable pharmacological properties make it an attractive candidate for further development as a therapeutic agent. Ongoing research continues to explore its full potential, with a focus on optimizing its efficacy and safety for clinical use.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)